Aromatase inhibitors in early breast-cancer treatment: The story so far

Breast

Volumn 17, Issue SUPPL. 3, 2008, Pages 2-8

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Early breast cancer; Exemestane; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; EXEMESTANE; LETROZOLE; MOLECULAR MARKER; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; EVIDENCE BASED MEDICINE; HUMAN; LYMPH NODE METASTASIS; MATHEMATICAL MODEL; METHODOLOGY; MONOTHERAPY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 49949152407     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.12.002     Document Type: Article

References (30)

1. Buzdar A., Chlebowski R., Cuzick J., et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 22 (2006) 1575-1585
2. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
3. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
4. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
5. Jones S.E. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer 6 Suppl 2 (2006) S41-S44
6. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
7. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
8. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369 (2007) 559-570
9. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
10. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
11. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a). J Clin Oncol (Meeting Abstracts) 2005; 23[16s part I of II]:10s.
12. Mamounas E.P. Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology 15 (2001) 35-39
13. Mamounas E, Jeong JH, Wickerham L, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. In: San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 14-17 December 2006.
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
15. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial efficacy and safety analyses. Cancer 98 (2003) 1802-1810
16. Nabholtz JM, Buzdar A. Impact of prior chemotherapy regimens on the relative efficacy of endocrine therapy: an exploratory analysis of data from the ATAC ('Arimidex', Tamoxifen, alone or in combination) trial on behalf of the ATAC Trialists' Group. Poster 210 presented at the 29th European Society of Medical Oncology Congress, Vienna, Austria, 29 October-2 November 2004.
17. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 365 (2005) 1308
18. Cuzick J., Sasieni P., and Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 94 (2006) 460-464
19. Cuzick J, Sasieni P, Howell A. Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: up front or sequenced after tamoxifen? J Clin Oncol 2007; ASCO Annu Meet Proc Part I; 25[18S].
20. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 1 (2008) 45-53
21. Punglia R.S., Kuntz K.M., Winer E.P., Weeks J.C., and Burstein H.J. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23 (2005) 5178-5187
22. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
23. Thurlimann B., Keshaviah A., Coates A., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
24. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
25. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (2007) 113-121
26. Punglia RS, Winer EP, Weeks JC, Burstein HJ. Could treatment with tamoxifen be superior to aromastase inhibitors in early stage breast cancer after pharmacogenomic testing? A modeling analysis. J Clin Oncol 2007; ASCO Annu Meeting Proc Part I; 25[18S].
27. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Nat Cancer Inst 95 (2003) 1758-1764
28. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
29. Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 (2007) R7
30. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 (2005) 249-258